Abraxane®

DRUG5 trials

Sponsors

OncoMed Pharmaceuticals, Inc., Theriva Biologics SL, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions

BioequivalenceLocally Advanced Solid TumorsMetastatic Pancreatic AdenocarcinomaMetastatic Solid TumorsPancreatic AdenocarcinomaPancreatic Cancer

Phase 1

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

CompletedNCT01189929

OncoMed Pharmaceuticals, Inc.Pancreatic Cancer

Start: 2010-08-31End: 2016-12-31Updated: 2020-09-09

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

CompletedNCT02045589

Theriva Biologics SLMetastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma

Start: 2014-01-31End: 2018-09-30Updated: 2018-10-01

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

CompletedNCT02045602

Theriva Biologics SLLocally Advanced Solid Tumors, Metastatic Solid Tumors, Pancreatic Adenocarcinoma

Start: 2014-01-31End: 2020-01-31Updated: 2020-10-08

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

RecruitingNCT07096869

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Bioequivalence

Start: 2025-06-26End: 2026-02-25Target: 28Updated: 2025-07-31

Phase 2

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

CompletedNCT02289898

OncoMed Pharmaceuticals, Inc.Pancreatic Cancer

Start: 2015-04-20End: 2017-09-30Updated: 2020-09-28

Related Papers

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.

2024-11-0610 citations

VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.

Journal of Clinical Oncology2024-06-011 citations

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer2022-03-0174 citations

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects

Journal for ImmunoTherapy of Cancer2021-11-0180 citations

A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer.

Journal of Clinical Oncology2016-02-0114 citations

A phase Ib study of the anti-cancer stem cell agent demcizumab (DEM) & gemcitabine (GEM) +/- paclitaxel protein bound particles (nab-paclitaxel) in pts with pancreatic cancer.

Journal of Clinical Oncology2015-05-2010 citations

A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer.

Journal of Clinical Oncology2014-01-207 citations